You are here

Duchenne Muscular Dystrophy

3 patients add $2.5B to Sarepta's value

3 patients add $2.5B to Sarepta's value

Biopharma Dive

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

With tantalizing early results, Sarepta’s gene therapy for Duchenne raises hopes for ‘real change’

With tantalizing early results, Sarepta’s gene therapy for Duchenne raises hopes for ‘real change’

Stat

Sarepta Therapeutics

Duchenne Muscular Dystrophy

clinical trials

Flag link:

As Sarepta Preps Data, FDA Lifts Hold on Solid’s Duchenne Gene Therapy

As Sarepta Preps Data, FDA Lifts Hold on Solid’s Duchenne Gene Therapy

Xconomy

Duchenne Muscular Dystrophy

Solid Biosciences

Sarepta Therapeutics

Flag link:

Sarepta’s eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drug

Sarepta’s eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drug

Endpoints

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

Catabasis Pharmaceuticals' Edasalonexent Slowed Duchenne Muscular Dystrophy Disease Progression Through One Year of Treatment

Catabasis Pharmaceuticals' Edasalonexent Slowed Duchenne Muscular Dystrophy Disease Progression Through One Year of Treatment

CP Wire

Duchenne Muscular Dystrophy

Flag link:

Catabasis Pharmaceuticals' Edasalonexent Slowed Duchenne Muscular Dystrophy Disease Progression Through One Year of Treatment

Duchenne Muscular Dystrophy

Flag link:

Daiichi Sankyo concedes an early setback on Duchenne MD drug, but doubles down on development

Daiichi Sankyo concedes an early setback on Duchenne MD drug, but doubles down on development

Endpoints

Duchenne Muscular Dystrophy

Flag link:

Solid Biosciences Provides Update on Clinical Hold of Ph I/II Trial for Duchenne Muscular Dystrophy (DMD)

Solid Biosciences Provides Update on Clinical Hold of Ph I/II Trial for Duchenne Muscular Dystrophy (DMD)

CP Wire

Solid Biosciences

Duchenne Muscular Dystrophy

clinical trials

Flag link:

Catabasis Pharmaceuticals Reduces Workforce by 42% to Focus on Developing Edasalonexent for Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals Reduces Workforce by 42% to Focus on Developing Edasalonexent for Duchenne Muscular Dystrophy

CP Wire

Duchenne Muscular Dystrophy

Flag link:

Solid Biosciences Provides Update on Clinical Hold of Ph I/II Trial for Duchenne Muscular Dystrophy (DMD)

Solid Biosciences

Duchenne Muscular Dystrophy

Flag link:

Catabasis Pharmaceuticals Reduces Workforce by 42% to Focus on Developing Edasalonexent for Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Flag link:

Pfizer Commences Ph Ib Trial With Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

Pfizer Commences Ph Ib Trial With Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

CP Wire

Duchenne Muscular Dystrophy

Flag link:

Should Sarepta’s patents be seized by the government? Patient advocates pitch controversial drug pricing proposal

Should Sarepta’s patents be seized by the government? Patient advocates pitch controversial drug pricing proposal

Endpoints

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

Solid Bio's DMD gene therapy graduates from partial FDA hold to full-on clinical hold

Solid Bio's DMD gene therapy graduates from partial FDA hold to full-on clinical hold

Fierce Biotech

Solid Biosciences

Duchenne Muscular Dystrophy

Flag link:

Sarepta to seek FDA approval for its second Duchenne’s drug by year’s end

Sarepta to seek FDA approval for its second Duchenne’s drug by year’s end

Stat

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

Did the FDA just leave the door cracked open for PTC’s Duchenne drug after repeated slapdowns?

Did the FDA just leave the door cracked open for PTC’s Duchenne drug after repeated slapdowns?

Endpoints

PTC Therapeutics

Duchenne Muscular Dystrophy

Flag link:

Sarepta halts its golodirsen Duchenne MD study in UK after patient experiences adverse event

Sarepta halts its golodirsen Duchenne MD study in UK after patient experiences adverse event

Endpoints

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

Merck R&D chief Roger Perlmutter offers some heavyweight R&D glam to a little upstart biotech out to cure Duchenne MD

Merck R&D chief Roger Perlmutter offers some heavyweight R&D glam to a little upstart biotech out to cure Duchenne MD

Endpoints

Roger Perlmutter

Duchenne Muscular Dystrophy

Exonics Therapeutics

Flag link:

Anthem reverses course, agrees to cover Sarepta's Duchenne drug

Anthem reverses course, agrees to cover Sarepta's Duchenne drug

BioPharma Dive

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

With $40M for Exonics, Duchenne’s Gene Therapy, CRISPR Race Heats Up

With $40M for Exonics, Duchenne’s Gene Therapy, CRISPR Race Heats Up

Xconomy

Exonics Therapeutics

Duchenne Muscular Dystrophy

Flag link:

Pages